What is GLSI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GLSI?

P/E (TTM) is n/a and 52-week range is $7.78 to $34.10 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GLSI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GLSI?

The company profile lists net income (TTM) near $-22M, EPS (TTM) near $-1.53 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Greenwich Lifesciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Stafford Texas, Texas, US, 14.7M shares outstanding, ISIN US3968791083 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Greenwich Lifesciences Inc

$GLSI

Health Care · Biotechnology

IR Run Scenarios

$16.53

+9.18%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. The company has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

Employees

Website

greenwichlifesciences.com

IPO

2020-09-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)